High occurrence of JAK2 V617 mutation in refractory anemia with ringed sideroblasts associated with marked thrombocytosis [16]

Leukemia

Volumn 20, Issue 11, 2006, Pages 2067-2070

  Verstovsek, S ^a   Silver, R T ^b   Cross, N C P ^c   Tefferi, A ^d  

^a UNIVERSITY OF TEXAS   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c SALISBURY DISTRICT HOSPITAL   (United Kingdom)

^d Mayo Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; JANUS KINASE 2;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; AMINO ACID SUBSTITUTION; BLOOD SAMPLING; BONE MARROW BIOPSY; CANCER SURVIVAL; CARCINOGENESIS; CHRONIC MYELOMONOCYTIC LEUKEMIA; CONTROLLED STUDY; CYTOGENETICS; DYSERYTHROPOIESIS; FEMALE; GENETIC ASSOCIATION; GENOTYPE; HUMAN; HUMAN CELL; HUMAN TISSUE; LETTER; MAJOR CLINICAL STUDY; MALE; MUTATION RATE; MUTATIONAL ANALYSIS; MYELODYSPLASTIC SYNDROME; MYELOID METAPLASIA; POINT MUTATION; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REFRACTORY ANEMIA WITH RINGED SIDEROBLASTS; SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVAL TIME; THROMBOCYTHEMIA; THROMBOCYTOSIS;

EID: 33750333065     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2404405     Document Type: Letter

References (10)

1. James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythemia vera. Nature 2005; 434: 1144-1148.
2. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005; 352: 1779-1790.
3. Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005; 7: 387-397.
4. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S et al. Cancer Genome Project. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365: 1054-1061.
5. Jelinek J, Oki Y, Gharibyan V, Bueso-Ramos C, Prchal JT, Verstovsek S et al. JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia. Blood 2005; 106: 3370-3373.
6. Vardiman JW. Myelodysplastic/myeloproliferative diseases. In: Jaffe ES, Harris NL, Stein H, Vardiman JW (eds). World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. IARC Press: Lyon, 2001, pp 47-59.
7. Remacha AF, Nomdedeu JF, Puget G, Estivill C, Sarda MP, Canals C et al. Occurrence of the JAK2 V617F mutation in the WHO provisional entity: myelodysplastic/myeloproliferative disease, unclassifiable refractory anemia with ringed sideroblasts associated with marked thrombocytosis. Haematologica 2006; 91: 719-720.
8. Szpurka H, Tiu R, Murugesan G, Aboudola S, Hsi ED, Theil KS et al. Refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T), another myeloproliferative condition characterized by JAK2 mutations. Blood 2006; 10.1182/ blood-2006-02-005751 (in press).
9. James C, Delhommeau F, Marzac C. Teyssandier I, Le Couedic JP, Giraudier S et al. Detection of JAK2 V617F as a first intention diagnostic test for erythrocytosis. Leukemia 2006; 20: 350-353.
10. Shaw GR. Ringed sideroblasts with thrombocytosis: An uncommon mixed myelodysplastic/myeloproliferative disease of older adults. Br J Haematol 2005; 131: 180-184.